Human disease
myasthenia gravis
Mondo defines it as: “Myasthenia gravis (MG) is a rare, clinically heterogeneous, autoimmune disorder of the neuromuscular junction characterized by fatigable weakness of voluntary muscles.”
1 disease group in OMIA reaches this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.
Animal diseases
By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.
| OMIA group | Name | Found by | Species | The chain reached | Score |
|---|---|---|---|---|---|
| 684 | Myasthenia | OMIA's OMIM numbers | 4 | Human disease |
40.0
|
Human genes
Each human gene of these disease groups that Open Targets links to this disease.
Open Targets links none of these groups' human genes to this disease.
Drugs tested for this disease
Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.
| Drug | Acts on | Latest stage for this disease |
|---|---|---|
| Ambenonium | None of these genes | Approved |
| Amifampridine | None of these genes | Approved |
| Edrophonium | None of these genes | Approved |
| Efgartigimod Alfa | None of these genes | Approved |
| Guanidine | None of these genes | Approved |
| Neostigmine | None of these genes | Approved |
| Nipocalimab | None of these genes | Approved |
| Pralidoxime | None of these genes | Approved |
| Pyridostigmine | None of these genes | Approved |
| Rozanolixizumab | None of these genes | Approved |
| Zilucoplan | None of these genes | Approved |
| Zilucoplan Sodium | None of these genes | Approved |
| Azathioprine | None of these genes | Phase 3 |
| Batoclimab | None of these genes | Phase 3 |
| Bq 788 | None of these genes | Phase 3 |
| Cemdisiran | None of these genes | Phase 3 |
| Cladribine | None of these genes | Phase 3 |
| Eculizumab | None of these genes | Phase 3 |
| Gefurulimab | None of these genes | Phase 3 |
| Human Immunoglobulin G | None of these genes | Phase 3 |
| Inebilizumab | None of these genes | Phase 3 |
| Iptacopan | None of these genes | Phase 3 |
| Leflunomide | None of these genes | Phase 3 |
| Mycophenolate Mofetil | None of these genes | Phase 3 |
| Pozelimab | None of these genes | Phase 3 |
| Prednisone | None of these genes | Phase 3 |
| Ravulizumab | None of these genes | Phase 3 |
| Remibrutinib | None of these genes | Phase 3 |
| Rituximab | None of these genes | Phase 3 |
| Satralizumab | None of these genes | Phase 3 |
| Sodium Chloride | None of these genes | Phase 3 |
| Tacrolimus Anhydrous | None of these genes | Phase 3 |
| Telitacicept | None of these genes | Phase 3 |
| Tolebrutinib | None of these genes | Phase 3 |
| Albuterol | None of these genes | Phase 2/3 |
| Blinatumomab | None of these genes | Phase 2/3 |
| Belimumab | None of these genes | Phase 2 |
| Bortezomib | None of these genes | Phase 2 |
| Iscalimab | None of these genes | Phase 2 |
| Methotrexate | None of these genes | Phase 2 |
| Mezagitamab | None of these genes | Phase 2 |
| Ondansetron | None of these genes | Phase 2 |
| Orilanolimab | None of these genes | Phase 2 |
| Tirasemtiv | None of these genes | Phase 2 |
| Tocilizumab | None of these genes | Phase 2 |
| Vemircopan | None of these genes | Phase 2 |
| Resecabtagene Autoleucel | None of these genes | Phase 1/2 |
| Ripertamab | None of these genes | Phase 1/2 |
| Antilymphocyte Immunoglobulin (Horse) | None of these genes | Phase 1 |
| Cizutamig | None of these genes | Phase 1 |
| Cyclophosphamide Anhydrous | None of these genes | Phase 1 |
| Filgrastim | None of these genes | Phase 1 |
| Fludarabine | None of these genes | Phase 1 |
| Lenograstim | None of these genes | Phase 1 |
| Oxaloacetate | None of these genes | Phase 1 |
| Pegfilgrastim | None of these genes | Phase 1 |
| Zolacabtagene Autoleucel | None of these genes | Phase 1 |
| Abatacept | None of these genes | Early phase 1 |
| Molgramostim | None of these genes | Early phase 1 |
| Regramostim | None of these genes | Early phase 1 |
| Sargramostim | None of these genes | Early phase 1 |
| Tofacitinib | None of these genes | Early phase 1 |
| Betamethasone | None of these genes | Unknown |
| Betamethasone Phosphoric Acid | None of these genes | Unknown |
| Dexamethasone | None of these genes | Unknown |
| Empasiprubart | None of these genes | Unknown |
| Hydrocortisone | None of these genes | Unknown |
| Methylprednisolone | None of these genes | Unknown |
| Mycophenolic Acid | None of these genes | Unknown |
| Prednisolone | None of these genes | Unknown |
| Sugammadex | None of these genes | Unknown |
| Talquetamab | None of these genes | Unknown |
| Triamcinolone | None of these genes | Unknown |
The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.